Gap Micro-401: Test, optimize and validate existing terrestrial or novel technologies that can maintain in-flight microbial counts, types, and virulence at terrestrial equivalent levels.
Last Published:  11/23/20 11:55:10 AM (Central)
Responsible Element: Human Health Countermeasures (HHC)
Status: Open
Description
Present state of knowledge: Current operational activities for in-flight environmental microbial control rely on terrestrially-derived practices and do not account for any microbial changes associated with spaceflight. Previous evidence suggests microorganisms may alter antimicrobial resistance and biofilm architecture in response to growth in the spaceflight environment.
Research approach: HRP plans to fund studies via solicited and directed mechanisms, using flight and analog data, including but not limited to identification and flight certification of existing or novel technologies (e.g. UV light, specialized wipes, introduction of a bacteriophage or other gene editing tools for making microbes more susceptible to destruction/hibernation/antibiotics) that would allow mitigation of in-flight microbial proliferation or unwanted changes. Other countermeasures, such as pharmaceuticals, including antibiotics, are being investigated by HRP’s Exploration Medical Capabilities (ExMC) Element. Use of probiotics and prebiotics as a countermeasure to changes in the crewmembers’ microbiomes are being investigated as part of HHC’s Immune and Food/Nutrition risks.
Target for Closure
Validated technologies for mitigation of microbial concerns.
Mappings
Risk Risk of Adverse Health Effects Due to Host-Microorganism Interactions
You are here! Gap Micro-401: Test, optimize and validate existing terrestrial or novel technologies that can maintain in-flight microbial counts, types, and virulence at terrestrial equivalent levels.
Completed
Planned-Funded

Documentation:
No Documentation Available